Is the multifunctional Na(+)/H(+) exchanger isoform 1 a potential therapeutic target in cancer?
C Stock1, F T Ludwig, A Schwab
1Institute of Physiology II, Robert-Koch-Str. 27b, 48149 Münster, Germany. cmstock@uni-munster.de
Abstract:
The Na(+)/H(+) exchanger isoform 1 (NHE1) is a ubiquitously expressed transporter fulfilling a variety of cell physiological tasks. By importing Na(+) and exporting H(+), NHE1 contributes to regulatory volume increase and cytoplasmic pH homeostasis. In addition it anchors the cytoskeleton in the plasma membrane. NHE1 plays a critical role in mediating the progression of reperfusion injuries after ischemia. Moreover, it is upregulated and/or overexpressed in a number of tumour cells. In many cases an elevated NHE1 activity can be correlated with an increase in cell motility and malignancy. Consequently, NHE1 including its regulators may represent potential targets in anticancer therapy. Different NHE1 inhibitors are compared and possible clinical exploitations of NHE1 inhibition are discussed.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
ABC Transporters: Exporter
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...


